Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322739 | 1.00 | ANPEP (0.43) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| Potassium SCHEMBL607194 | 0.98 | ANPEP (0.42) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL607192 | 0.98 | ANPEP (0.42) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL1710560 | 0.96 | ANPEP (0.41) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| Hydrochloric Acid SCHEMBL1860705 | 0.96 | ANPEP (0.41) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL15859443 | 0.86 | SLC6A12 (0.37) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL606928 | 0.86 | SLC6A12 (0.37) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL337044 | 0.81 | GRM1 (0.38) | ANPEPENPEPGRM1POLBTDP1 | |
| SCHEMBL337453 | 0.81 | BRD4 (0.43) | GRM1ALDH1A1DAOKCNQ3KCNQ2 | |
| SCHEMBL10086748 | 0.81 | BRD4 (0.43) | GRM1ALDH1A1DAOKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038282-A1 | 2-AZA- AND 2-OXABICYCLO[2.1.1]HEXANE DERIVATIVES AS FACTOR XIIA ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | CORSAIR PHARMA INC (US) | 2017-10-19 | — | — | US | disclosed |
| CN-107207472-A | Inhibitors of AKT kinase | 卑尔根生物股份公司 | 2017-09-26 | — | — | CN | disclosed |
| US-9701616-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9643911-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2017-05-09 | — | — | US | disclosed |
| WO-2012117001-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120225868-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-06 | — | — | US | disclosed |
| WO-2012110470-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| EP-2344482-B1 | BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| WO-2012004206-A1 | ANELLATED PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | ANPEP 2000/4885ENPEP 1055/4885SLC6A1 1605/4885 |
| US-20170298001-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | ANPEP 427/4885ENPEP 179/4885SLC6A1 1963/4885 |
| US-20120225868-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | HTR2A, HTR2C, HTR1D | ANPEP 3753/4885ENPEP 4665/4885SLC6A1 891/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | ANPEP 2013/4885ENPEP 1070/4885SLC6A1 1666/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | ANPEP 2013/4885ENPEP 1070/4885SLC6A1 1666/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | ANPEP 390/4885ENPEP 824/4885SLC6A1 2735/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | ANPEP 2000/4885ENPEP 1055/4885SLC6A1 1605/4885 |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | ANPEP 2850/4885ENPEP 3708/4885SLC6A1 1958/4885 |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | ANPEP 2821/4885ENPEP 3842/4885SLC6A1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.